A randomized control trial to evaluate the effect of adjuvant selective laser trabeculoplasty versus medication alone in primary open-angle glaucoma: preliminary results by Chan, JCH et al.
Title
A randomized control trial to evaluate the effect of adjuvant
selective laser trabeculoplasty versus medication alone in
primary open-angle glaucoma: preliminary results
Author(s) Lee, WYJ; Chan, CW; Wong, MO; Chan, JCH; Li, Q; Lai, JS
Citation Clinical Ophthalmology, 2014, v. 8, p. 1987-1992
Issued Date 2014
URL http://hdl.handle.net/10722/208490
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© 2014 Lee et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Clinical Ophthalmology 2014:8 1987–1992
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1987
O r i g i n a l  r e s e a r C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OPTH.S70903
a randomized control trial to evaluate the effect 
of adjuvant selective laser trabeculoplasty versus 
medication alone in primary open-angle glaucoma: 
preliminary results
Jacky WY lee1,2
Catherine Ws Chan2
Mandy OM Wong3
Jonathan Ch Chan3
Qing li2
Jimmy sM lai2
1The Department of Ophthalmology, 
Caritas Medical Centre, 
2The Department of Ophthalmology, 
The University of hong Kong,  
3The Department of Ophthalmology, 
Queen Mary hospital, hong Kong
Background: The objective of this study was to investigate the effects of adjuvant selective 
laser trabeculoplasty (SLT) versus medication alone on intraocular pressure (IOP) control, 
medication use, and quality of life in patients with primary open-angle glaucoma.
Methods: This prospective, randomized control study recruited 41 consecutive primary open-
angle glaucoma subjects with medically-controlled IOP 21 mmHg. The SLT group (n=22) 
received a single 360-degree SLT treatment. The medication-only group (n=19) continued with 
their usual treatment regimen. In both groups, medication was titrated to maintain a target IOP 
defined as a 25% reduction from baseline IOP without medication, or 18 mmHg, whichever 
was lower. Outcomes, which were measured at baseline and at 6 months, included the Glaucoma 
Quality of Life-15 (GQL-15) and Comparison of Ophthalmic Medications for Tolerability 
(COMTOL) survey scores, IOP, and the number of antiglaucoma medicines. 
Results: The baseline IOP was 15.8±2.7 mmHg and 14.5±2.5 mmHg in the SLT and medication-
only groups, respectively (P=0.04). Both groups had a comparable number of baseline medication 
(P=0.2), GQL-15 (P=0.3) and COMTOL scores (P=0.7). At 6 months, the SLT group had a 
lower IOP (P=0.03) and required fewer medications compared with both baseline (P0.0001) 
and with the medication-only group (P=0.02). There was no statistically significant difference 
in the 6-month GQL-15 or COMTOL score as compared to baseline (P0.4) or between the 
two treatment groups (P0.2).
Conclusion: A single session of adjuvant SLT provided further reductions in IOP and medica-
tion without substantial changes in quality of life or medication tolerability at 6 months. 
Keywords: quality of life, intraocular pressure, antiglaucoma medication
Introduction
Primary open-angle glaucoma (POAG) is characterized by a progressive glaucoma-
tous optic neuropathy. One of the most recognized risk factors associated with POAG 
is elevated intraocular pressure (IOP), ie, 21 mmHg. Accordingly, many patients 
require multiple antiglaucoma medications to regulate IOP. Although medication may 
provide adequate IOP control, it is associated with numerous side effects and may even 
compromise patients’ quality of life (QoL). Additionally, because antiglaucoma drops 
are somewhat inconvenient to use, treatment compliance is a significant issue.1 
Selective laser trabeculoplasty (SLT) is a noninvasive laser procedure that can 
increase aqueous outflow by increasing the porosity of the trabecular meshwork from 
the upregulation of metalloproteinases, cytokines, and macrophages.2 SLT offers simi-
lar long-term IOP-lowering effects as medical therapy alone but has minimal adverse 
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effects. Moreover, because SLT does not cause collateral 
damage to the surrounding tissue, it can be repeated.3 SLT 
also has the potential to reduce antiglaucoma medication use, 
which may potentially improve patients’ QoL.4 
The Early Manifest Glaucoma Trial demonstrated that 
there was no significant difference in health-related QoL 
between patients treated with a topical beta-blocker plus 
argon laser trabeculoplasty versus no treatment in newly-
diagnosed POAG patients.5 Additionally, the Collaborative 
Initial Glaucoma Treatment Study showed no substantial dif-
ference in QoL between those treated with medication versus 
filtration surgery in newly-diagnosed POAG patients.6 
Currently, published literature evaluating the role of 
adjuvant SLT for POAG patients who are already on antiglau-
coma medication is somewhat limited. Consequently, the aim 
of the study was to investigate the efficacy of adjuvant SLT 
versus medication alone in terms of IOP control, medication 
requirement and tolerability, and glaucoma-specific QoL in 
patients with POAG.
Patients and methods
This was a prospective, randomized controlled study con-
ducted at a university hospital in Hong Kong, from June 
2012 to March 2013. Ethics approval by the institutional 
review board was obtained prior to study commencement, 
and all patients were required to provide written informed 
consent. The study was registered with the Clinical Trials 
Register of the University of Hong Kong (HKCTR-1597) 
and complied with the principles outlined in the Declaration 
of Helsinki.7
The inclusion criteria consisted of consecutive subjects 
aged 18 years, with preexisting bilateral POAG with IOP 
medically-controlled to 21 mmHg. POAG was defined as 
an open angle on gonioscopy, presenting IOP 21 mmHg, 
and visual field loss on the Humphrey visual field analyzer 
as per the Hodap–Parrish–Anderson criteria,8 or retinal nerve 
fiber layer thinning on optical coherence tomography. All 
subjects were using at least one antiglaucoma medication in 
each eye prior to study recruitment. The exclusion criteria 
included those with secondary glaucomas, angle-closure 
glaucomas, a follow-up history of less than 6 months, illit-
eracy, and previous laser or surgical procedure for glaucoma. 
SLT was offered for patients with the aim of reducing the 
number of antiglaucoma medications required. 
In both groups, an individual target IOP was determined 
as a 25% reduction in IOP from the first presentation (before 
the use of antiglaucoma medication), as per the findings of the 
Early Manifest Glaucoma Trial,9 or an IOP 18 mmHg as 
per the Advanced Glaucoma Intervention Study,10 whichever 
was lower. 
Subjects were randomized into two groups (the SLT 
group and the medication-only group) based on a computer-
generated random sequence. The SLT group received a single 
SLT treatment via a Q-switched Nd:YAG laser (Ellex Solo™; 
Ellex Medical Pty. Ltd., Adelaide, Australia), with initial 
energy of 0.8 mJ and titrated until bubble formation was 
just visible. Treatment was delivered by a single glaucoma 
specialist (JWYL), in a single burst mode to 360 degrees 
of the trabecular meshwork. Both eyes were treated in the 
same laser session. In all treated eyes, a drop of Alphagan P 
(Allergan Inc., Waco, TX, USA) was instilled post-SLT, and 
a dexamethasone 0.1% and neomycin 0.5% combination eye 
drop (Dexoptic-N; Ashford Laboratories Pvt. Ltd., Mumbai, 
India) was used twice daily for 1 day, although treatment 
was continued for several days if anterior chamber reaction 
was seen 1 day post-SLT. Subjects returned for follow-up at 
1 day, 1 week, and 1 month after SLT, and every 3 months 
thereafter. 
Subjects continued on the same pre-SLT antiglaucoma 
eye drops post-SLT. At 1 month postoperatively, antiglau-
coma eye drops were titrated based on the individual clini-
cal response in order to reach their target IOP as detailed 
above. The medication-only group continued their current 
antiglaucoma eye drops with titrations made to their current 
regimen to maintain their target IOP during follow-up every 
3 months. In both groups, medications were added in the fol-
lowing sequence if the target IOP was not met: prostaglandin 
analogues or beta-blockers, followed by alpha-adrenergic 
agonist or topical carbonic anhydrase inhibitor, then pilo-
carpine. Likewise, if the IOP was well below the target 
IOP, medications were removed in the following sequence: 
pilocarpine, followed by alpha-adrenergic agonist or topical 
carbonic anhydrase inhibitor, then prostaglandin analogues or 
beta-blockers. Where required, fixed combination eye drops 
were prescribed to simplify drug regimens and were counted 
as two types of medication in the analysis. Medications were 
changed either to improve IOP control or in cases of reported 
drug intolerance. 
Traditional Chinese translated versions of the Glaucoma 
Quality of Life-15 (GQL-15) and the Comparison of Oph-
thalmic Medications for Tolerability (COMTOL) surveys 
were completed by all subjects at baseline and at 6 months. 
The GQL-15 questionnaire is a glaucoma-specific, writ-
ten questionnaire that assesses patients’ perceived visual 
disability in 15 daily tasks. The tasks are categorized in 
four areas of visual disability: 1) central and near vision, 
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2) peripheral vision, 3) dark adaptation and glare, and 
4) outdoor mobility. A 5-point rating scale for the level of 
difficulty of each task totals a score from 0 to 75. A higher 
score signifies a poorer QoL (Table 1).
The COMTOL questionnaire is a consistent, reliable, and 
reproducible assessment of the local side effects of topical 
antiglaucoma medications.11–13 We simplified the original 
COMTOL by eliminating the subscales that further quanti-
fied the degree of severity and frequency of the side effects. 
Patients were simply asked to identify whether or not they 
had experienced any of the 15 local side effects from the 
COMTOL checklist to produce a “side effects score” from 
0 to 15. A higher score signifies a greater intolerability to 
the medication (Table 2).
The questionnaires were translated from English to 
Chinese by an investigator who was fluent in both languages 
followed by a back translation by another investigator. To 
then ensure the accuracy of the translation, the translated 
questionnaire was tested on five POAG patients of varying 
sex and age. Patients were asked to complete the question-
naires in addition to offering their interpretation of the 
contents in the questionnaire and were invited to suggest 
alternative wording if necessary. 
In addition to GQL-15 and COMTOL scores, the main 
outcome measures were IOP and the number of antiglaucoma 
medications used at baseline and 6 months. All IOPs were 
measured by a single observer using Goldmann applanation 
tonometry either on Tuesday afternoons or Thursday morn-
ings, and patients were advised to return for follow-up during 
the same time periods to minimize diurnal variability. To 
limit bias, the observer attempted to record the IOP prior to 
studying the patient’s medical records. 
statistical analysis 
Statistical calculations were performed using GraphPad 
Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). 
The Mann–Whitney U-test and the Wilcoxon signed rank 
test were used to compare differences in IOP, GQL-15, 
COMTOL, and number of antiglaucoma medications at 
baseline and 6 months between the SLT and the medication-
only group. Based on the sample size of 41 patients, a 40% 
difference in the number of medications used at 6 months 
between the two treatment arms, and an alpha error of 0.05, 
the calculated power of this study was 86.4%. All means 
were expressed as mean ± standard deviation. Statistical 
significance was defined as P0.05. 
Results
The study included 41 patients, 22 in the SLT group and 19 in 
the medical group. Demographic and baseline characteristics 
for both groups are described in Table 3.
The SLT group received 121.8±30.0 laser shots at a mean 
energy of 0.9±0.05 mJ. There were no complications from the 
laser procedure. At 1 day, 1 week, and 1 month post-SLT, IOPs 
were 11.9±2.5 mmHg, 13.6±3.3 mmHg, and 13.6±2.9 mmHg, 
respectively.
At 6 months, the IOP in the SLT group (13.4±2.3 mmHg) 
had reduced by 15.2% from baseline (P0.0001) and was 
7.6% lower than the medication-only group (P=0.03) (Table 4). 
Compared to baseline, the overall IOP reduction was 40.9% in 
the SLT group and 41.9% in the medication-only group. 
At 6 months, the SLT group required 34.8% fewer 
number of antiglaucoma medications compared to baseline 
(P0.0001) and 40.0% fewer antiglaucoma eye drops 
compared to the medication-only group (Table 4). The most 
Table 1 The glaucoma Quality of life-15 questionnaire
Does your vision give you any difficulty, even  
with glasses, with the following activities? 
None A little bit Some Quite a lot Severe Do not perform 
for nonvisual reasons
reading newspapers 1 2 3 4 5 0
Walking after dark 1 2 3 4 5 0
seeing at night 1 2 3 4 5 0
Walking on uneven ground 1 2 3 4 5 0
adjusting to bright lights 1 2 3 4 5 0
adjusting to dim lights 1 2 3 4 5 0
going from light to dark room or vice versa 1 2 3 4 5 0
Tripping over objects 1 2 3 4 5 0
seeing objects coming from the side 1 2 3 4 5 0
Crossing the road 1 2 3 4 5 0
Walking on steps/stairs 1 2 3 4 5 0
Bumping into objects 1 2 3 4 5 0
Judging distance of foot to step/curb 1 2 3 4 5 0
Finding dropped objects 1 2 3 4 5 0
recognizing faces 1 2 3 4 5 0
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commonly used antiglaucoma medications were prostaglan-
din analogues and beta-blockers in both treatment arms at 
baseline and 6 months (Table 5).
The 6-month GQL-15 score was similar between the 
SLT (23.7±9.0) and the medication-only groups (28.0±12.5) 
(P=0.2), and there was no significant improvement from base-
line scores in either group (P0.4) (Table 4). The 6-month 
COMTOL score was also similar between the SLT (3.7±3.6) 
and medication-only group (4.7±4.4) (P=0.5). As per GQL-15, 
there was no significant improvement from baseline scores in 
either group (P0.6) (Table 4). 
Discussion
To the best of our knowledge, this is one of the first random-
ized control trials comparing QoL in POAG patients treated 
with adjuvant SLT versus medication alone. All subjects in 
our study had preexisting POAG that was medically con-
trolled with antiglaucoma eye drops. The baseline IOP was 
slightly higher in the SLT group, with both groups requiring 
approximately two types of antiglaucoma eyes drops. How-
ever, at 6 months, the SLT group had a 7.6% lower IOP and 
required 40.0% less medication compared to the medical 
group. Both the SLT (40.9%) and the medication-only group 
(41.9%) achieved a similar percentage of IOP reduction 
compared to their IOP on first presentation. 
QoL questionnaires in glaucoma can be categorized into 
general health-related, vision-specific, or glaucoma-specific.14 
Of the 18 different glaucoma-specific patient-reported QoL 
assessments available, the GQL-15 and the Vision Quality 
of Life Index are more favorable in terms of their content, 
validity, and reliability.15 The GQL-15 assesses four areas 
of visual disability: 1) central and near vision, 2) peripheral 
vision, 3) dark adaptation and glare, and 4) outdoor mobil-
ity. In both the SLT and medical group, dark adaptation was 
the area of greatest difficulty, namely the task of “seeing 
at night.” At baseline, both treatment groups had a similar 
GQL-15 score. At 6 months, the GQL-15 score was reduced 
by 6.3% in the SLT group and 3.7% in the medical group 
as compared to baseline although this difference was not 
statistically significant. Additionally, there was no significant 
difference between the two treatment groups at 6 months. 
Given the statistically significant reduction in IOP and 
antiglaucoma eye drops in the SLT group, we had expected an 
improvement in QoL from baseline or at least in comparison 
with the medical group at 6 months, but this was not the case. 
This finding can be explained by the fact that the existing 
glaucoma-specific surveys including the GQL-15 may not 
be sensitive enough to fully account for the contributions of 
reduced antiglaucoma medication or lowered IOP in relation 
to QoL, especially when the drop in IOP occurs within a 
normal pressure range of 21 mmHg. It is also possible that 
the design of these glaucoma-specific surveys focus primar-
ily on changes in vision, visual field, and dark adaptations, 
rather than on patient’s satisfaction with antiglaucoma drugs. 
Hence, we supplemented the GQL-15 with the COMTOL 
checklist to investigate the side effects and tolerability of 
antiglaucoma eye drops. 
There is limited data in the literature reporting a direct 
association between the side effects of topical antiglaucoma 
medication and QoL. Nordmann et al13 reported that 62.4% 
of patients had at least one local side effect from topical 
antiglaucoma medications. Specifically, 25.4% had burning, 
20.8% had blurring, and 20.2% had tearing after use, resulting 
in low treatment satisfaction and poorer QoL. Skalicky et al16 
also reported that 59% of glaucoma patients had Ocular 
Surface Disease (OSD) due to benzalkonium chloride, the 
Table 2 Comparison of ophthalmic medications for tolerability 
checklist
Burning
Blurred vision
Tearing
itchy eyes
Dimming of vision
Discharge from eyes
Focusing
reading
redness
Bitter taste
swelling
Dry eyes
Trouble seeing at night
Unusual taste
Brow ache
Table 3 Demographic and baseline characteristics between the 
slT and medical group
Parameters SLT group Medical group P-value
age (years) 66.5±13.6 65.5±12.7 0.9
sex (M:F) 1.2:1 1.1:1 0.9
Presenting iOP  
(without medication)
22.7±3.7 mmhg 25.0±4.3 mmhg 0.04
Baseline iOP 15.8±2.7 mmhg 14.5±2.5 mmhg 0.04
Types of  
antiglaucoma eye  
drops at baseline
2.3±1.1 2.1±0.9 0.3
gQl-15 score 25.3±12.7 29.1±12.1 0.3
COMTOl score 4.2±3.0 4.6±4.0 0.7
Abbreviations: COMTOl, Comparison of Ophthalmic Medications for Tolerability 
survey; F, female; gQl, glaucoma Quality of life questionnaire; iOP, intraocular 
pressure; M, male; slT, selective laser trabeculoplasty.
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preservative in eye drops, and that those with OSD had 
poorer glaucoma-specific QoL. The COMTOL checklist 
showed good-to-excellent internal consistency (0.73 to 0.98), 
reliability (0.76 to 0.94), and reproducibility (0.75 to 0.93) 
in the assessment of medication side effects.11 We found a 
similar pattern in the COMTOL score as with the GQL-15 
score. There was an 11.9% reduction in the COMTOL score 
in the SLT group from baseline to 6 months and an increase 
of 2.2% in the medical group, but these changes were not 
statistically significant, nor was there a significant difference 
in the COMTOL scores between the two treatment groups at 
6 months. With a 34.8% reduction in antiglaucoma medication 
use in the SLT group at 6 months compared to baseline and a 
40.0% reduction in antiglaucoma medication use compared 
to the medication-only group at 6 months, we had expected 
a significant difference in the COMTOL score at 6 months 
for the SLT group. Our findings suggest that there may not 
be a direct association between medication side effects and 
glaucoma-specific QoL, and that patients’ perceived drug 
tolerability and local side effects may not be directly associ-
ated with the actual number of antiglaucoma medications 
used. A patient with intolerance to a single medication may 
be very dissatisfied, while a patient on multiple antiglaucoma 
medications may be satisfied with the treatment if they per-
ceive the side effects to be tolerable. 
Our study clearly has several limitations. First, the ran-
domized nature of this study produced unequal group sizes. 
Ideally, there would be an equal number of patients in each 
group; however, the use of restricted randomization or forced 
equality methods could potentially compromise treatment 
assignments and selection bias.17 Second, the translation of 
the original English based questionnaires was inevitable in a 
population where Chinese is the predominant dialect. Every 
effort was made to ensure that the translation was coherent 
Table 4 slT versus medical group at baseline and 6 months
SLT group  
(SLT + medication)
Medication-only  
group 
P-value (SLT group versus 
medication-only group)
iOP Baseline 15.8±2.7 mmhg 14.5±2.5 mmhg 0.04*
6 months 13.4±2.3 mmhg 14.5±2.2 mmhg 0.03*
Change from baseline -15.1% 0.0% _
P-value (baseline vs
6 months)
0.0001* 1.0 _
number of  
antiglaucoma  
medication
Baseline 2.3±1.1 types 2.1±0.9 types 0.3
6 months 1.5±1.2 types 2.1±1.0 types 0.02*
Change from baseline -34.8% 0.0% _
P-value (baseline vs
6 months)
0.0001* 0.8 _
gQl-15 score Baseline 25.3±12.7 29.1±12.1 0.3
6 months 23.7±9.0 28.0±12.5 0.2
Change from baseline -6.3% -3.7% _
P-value (baseline vs
6 months)
0.4 0.6 _
COMTOl score Baseline 4.2±3.0 4.6±4.0 0.7
6 months 3.7±3.6 4.7±4.4 0.5
Change from baseline -11.9% 2.2% _
P-value (baseline vs
6 months)
0.6 1.0 _
Note: *Represents statistical significance.
Abbreviations: COMTOl, Comparison of Ophthalmic Medications for Tolerability survey; gQl, glaucoma Quality of life questionnaire; iOP, intraocular pressure; slT, 
selective laser trabeculoplasty; vs, versus.
Table 5 Types of antiglaucoma medication used in both treatment arms at baseline and 6 months
Prostaglandin  
analogue (%)
β-blocker  
(%)
Alpha-agonist  
(%)
Topical carbonic  
anhydrase inhibitor (%)
Pilocarpine 
(%)
Baseline slT group 33.3 33.3 17.6 13.7 2.0
Medication-only group 31.4 34.3 22.9 11.4 0.0
6 months slT group 47.1 32.4 8.8 11.8 0.0
Medication-only group 30.0 40.0 20.0 10.0 0.0
Abbreviation: slT, selective laser trabeculoplasty.
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
13
1 
on
 2
4-
O
ct
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1992
lee et al
with the original questionnaire both linguistically and con-
ceptually via direct and back translations. Third, while all 
patients had POAG, we did not account for the differences in 
angle pigmentation. A pigmented angle could have improved 
SLT response, although the variability in an ethnic Chinese 
population would be minimal. Fourth, we did not account 
for the variability in drug adherence, which can affect the 
duration of exposure of medication. Fifth, the SLT group had 
a higher baseline IOP than the medical group and regression 
to the mean could have contributed to the reduction of IOP 
in the SLT group at 6 months. However, even if the 6-month 
IOPs were similar in both groups, more importantly, the SLT 
group required 40% less antiglaucoma medication than the 
medication-only group. Lastly, the titration of antiglaucoma 
medication was necessary for the clinical management of 
patients. To reduce bias, a preset individual target IOP was 
defined prior to the study and a medication adjustment 
algorithm was followed by the investigator. 
Overall, our findings suggest that adjuvant SLT in those 
with medically-controlled POAG can further lower IOP and 
reduce the antiglaucoma medication required. However, there 
was no significant difference in the glaucoma-specific QoL 
or treatment tolerability when compared to their pre-SLT 
state, or when compared to those receiving medication alone 
at 6 months after treatment.
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